Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombo- cythemia and b-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders

Acta Haematologica

Volumn 122, Issue 1, 2009, Pages 46-49

  Musolino, Caterina ^a   Allegra, Alessandro ^a   Penna, Giuseppa ^a   Centorrino, Raffaella ^a   Cuzzola, Maria ^b   D'Angelo, Arianna ^a   Iacopino, Pasquale ^b   Alonci, Andrea ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Essential thrombocythemia; JAK2; Lymphoproliferative diseases; Myeloproliferative neoplasms

Indexed keywords

JANUS KINASE 2;

AGED; ARTICLE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC RISK; GRANULOCYTE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LYMPHOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; MALE; MOLECULAR GENETICS; PRIORITY JOURNAL; RARE DISEASE; RISK FACTOR; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTHEMIA;

AGED; B-LYMPHOCYTES; FEMALE; GRANULOCYTES; HUMANS; JANUS KINASE 2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; T-LYMPHOCYTES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 70349827133     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000243721     Document Type: Article

References (33)

1. Kralovics R, Skoda RC: Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005; 19: 1-13.
2. Rashind WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ: Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest 1985; 75: 1388-1390.
3. Bohm J, Schaefer HE, Fish P: Coincidence of chronic idiopathic myelofibrosis and chronic lymphocytic leukaemia. A rare phenomenon? Pathologe 2002; 23: 480-485.
4. Bizzaro N: Chronic lymphocytic leukaemia in a patient with essential thrombocythaemia. Clin Lab Haematol 1998; 20: 377-379.
5. Nieto LH, Raya Sanchez JM, Arguelles HA, Brito Barroso ML, Gonzalez BG: A case of chronic lymphocytic leukemia overwhelmed by rapidly progressive idiopathic myelofibrosis. Haematologica 2000; 85: 973-977.
6. Bhagavathi S, Borromeo V, Desai H, Crison D: Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. Ann Clin Lab Sci 2008; 38: 405-409.
7. Burkhard R, Jaeger K, Kettner G, Helmer G: Chronic myeloproliferative disorders: prognostic importance of new working classification. J Clin Pathol 1990; 43: 357-364.
8. Skai L, Jakso P, Egyed M, Ivanyi JL, Radvanyi G, Dombi P, Pal K, Losonczy H: Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders. Mod Pathol 2004; 17: 1521-1530.
9. Pajor L, Lacza A, Kereskai L, Jakso P, Egyed M, Ivanji JL, Radvanyi G, Dombi P, Pal K, Losonczy H: Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders. Mod Pathol 2004; 17: 1521-1530.
10. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human proliferative disorders. Lancet 2005; 365: 1054-1061.
11. Lasho TL, Mesa R, Gilliland DG, Teferi A: Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2 V617F in granulocytes. Br J Haematol 2005; 130: 797-799.
12. Hussein K, Brakensie K, Ballmeier M, Bormann M, Gohring G, Buhr T, Bock O, Kreipe H: B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006; 77: 539-541.
13. Ishii T, Bruno E, Hoffman R, Xu M: Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera. Blood 2006; 108: 3128-3134.
14. Tabaczewski P, Nadesar S, Lim SH: Zap-70 positive chronic lymphocytic leukemia coexisting with JAK2 V617F positive essential thrombocythemia: a common defective stemm cell? Leuk Res 2009; 33: 854-855.
15. Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey, Gattermann, Armstrong S, Lock AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MWN: The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
16. Joos S, Kupper M, Ohl S, von Bonin F, Mechtorsheimer G, Benta M, Morynen G, Moller P, Pfeunschu M, Trumper L, Lichter P: Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000; 60: 549-552.
17. Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, Le Gouvello S, Gaulard P, Leroy K, Castellano F: Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 643-649.
18. Meizner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, Lenthauser F, Moller P: Biallelic mutation of SOCS-1 impairs JAK-2 degradation and sustains phosphor-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105: 2535-2542.
19. Kondo M, Scherer DC, King AG, Manz MG, Weissman IL: Lymphocyte development from hematopoietic stem cells. Curr Opin Genet Dev 2001; 11: 520-526.
20. Hou YH, Srour EF, Ramsey H, Dahl R, Broxmeyer HE, Hromas R: Identification of a human B-cell/myeloid common progenitor by the absence of CXCR4. Blood 2005; 105: 3488-3492.
21. Bacher U, Haferlach T, Kern W, Harich HD, Schnittger S, Haferlach C: A case of chronic myeloproliferative syndrome followed by precursor T-cell lymphoblastic leukemia. Cancer Genet Cytogenet 2007; 175: 52-56.
22. Henry L, Carillo S, Jourdan E, Arnaud A, Brun S, Lavabre-Bertrand T: Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol 2007; 82: 500-501.
23. Meier C, Holler S, Bourgeau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A: Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-Stat cascade in lymphomas. Mod Pathol 2009; 22: 476-487.
24. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A: Extending Jak2 V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007; 25: 2358-2362.
25. Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A: Demonstration of MPLW515K, but not JAK2 V617F , in in vitro expanded CD4+ T lymphocytes. Leukemia 2007; 21: 2206-2207.
26. Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A: Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V 1 Fpositive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 2007; 35: 1668-1676.
27. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y: JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5: 859-861.
28. Michiels JJ, Commandeur S, Hoogenboom GJ, Wegmann JJ, Scholten L, van Rijssel RH, De Raeve H: JAK2 V617F positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007; 86: 793-800.
29. Sidon P, El Housni H, Dessors B, Heimann P: The JAK2 V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.
30. Wang YL, lee JW, Kui JJ, Chadburn A, Cross NC, Knowles DM, Coleman M: Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2 V617F mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Hematol 2007; 118: 209-214.
31. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR: A gain of function, mutation of JAK2 in myeloproliferative disorders. N Eng J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
32. Goldgartd DE, Easton DF, Cannon Albright LA, Skolnick MH: Systematic populationbased assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600-1608.
33. Capalbo S, Callea V, Musolino C, Guglielmo P, D'Arena G, Fragasso A, Battista C, Giustolisi R, Brugiadelli M, Liso V: Familial Bcell chronic lymphocytic leukemia in a population of patients from Southern Italy. Int J Hematol 2004; 79: 1.